Hyperfine (HYPR) Stock Price, News & Analysis

Company Overview

Hyperfine, Inc. (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients. Hyperfine’s portable MRI is configured for rapid, point-of-care imaging of the brain and central nervous system, with applications spanning stroke evaluation, traumatic brain injury assessment and routine neurological monitoring. The system’s cloud-based image management and AI-assisted processing tools help streamline workflow and accelerate diagnostic decision-making.

Founded in 2014 and headquartered in Guilford, Connecticut, Hyperfine secured U.S. Food and Drug Administration 510(k) clearance for its portable MRI in 2020 and obtained CE mark authorization for its European operations in 2021. The company completed its business combination and began trading publicly on Nasdaq in 2022. Hyperfine continues to expand its commercial footprint across the United States and selective international markets, partnering with hospitals, health systems and research institutions to integrate portable MRI into standard clinical practice.

Key Stats

• Today's Range: $1.38 to $1.50
• 50-Day Range: $1.03 to $1.75
• 52-Week Range: $0.66 to $2.22
• Volume: 424,075 shs
• Average Volume: 556,481 shs
• Market Capitalization: $136.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.78
• Consensus Rating: Hold

Hyperfine Stock Analysis - MarketRank™

Hyperfine scored higher than 59% of companies evaluated by MarketBeat, and ranked 466th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Hyperfine has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Hyperfine has a consensus price target of $1.78, representing about 29.2% upside from its current price of $1.38.

Amount of Analyst Coverage

Hyperfine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hyperfine is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hyperfine is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hyperfine has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.17% of the float of Hyperfine has been sold short.

Short Interest Ratio / Days to Cover

Hyperfine has a short interest ratio ("days to cover") of 1.97, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hyperfine has recently increased by 54.37%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hyperfine does not currently pay a dividend.

Dividend Growth

Hyperfine does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.28

News Sentiment

Hyperfine has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Hyperfine this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for HYPR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

1 people have added Hyperfine to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hyperfine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $78,490.00 in company stock.

Percentage Held by Insiders

26.33% of the stock of Hyperfine is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

15.03% of the stock of Hyperfine is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 6/05/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HYPR
• CIK: 1833769
• Web: hyperfine.io
• Phone: 866-796-6767
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hyperfine: $1.78
• High Price Target: $2.50
• Low Price Target: $0.85
• Potential Upside/Downside: +29.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.57 million
• Net Margins: -226.88%
• Pretax Margin: -226.88%
• Return on Equity: -98.83%
• Return on Assets: -67.09%

Debt

• Debt-to-Equity Ratio: 0.38
• Current Ratio: 5.52
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: $11.40 million
• Price / Sales: 12.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.42 per share
• Price / Book: 3.29

Miscellaneous

• Outstanding Shares: 99,270,000
• Free Float: 73,132,000
• Market Cap: $136.99 million
• Optionable: Optionable
• Beta: 1.38